Cancer Research UK has invested £10m in the PRECISION Panc project, designed to include a network of clinical trials for the treatment of pancreatic cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The PRECISION Panc project is a research programme to develop personalised treatments for the patients, providing options and outcomes for better survival.

The programme will include three trials and enrol a total of 658 patients from a number of centres across the UK.

Funded by Celgene and Cancer Research UK, the PRIMUS 001 trial will evaluate Celgene's FOLFOX-A (FOLFOX and nab-paclitaxel) compared to GA (gemcitabine and nab-paclitaxel (SOC) in advanced disease patients.

Another trial known as PRIMUS 002 will include patients where the disease can be surgically removed.

The AstraZeneca / Medimmune supported PRIMUS 003 trial will involve immunotherapy for advanced disease patients.

Cancer Research UK pancreatic cancer expert and University of Glasgow professor Andrew Biankin said: “PRECISION Panc aims to transform how we treat pancreatic cancer by matching the right treatment to the right patient.

“Because the disease is so aggressive, patients may receive no treatment at all or if they are given an option it will be for just one line of treatment, so it’s essential that the most suitable treatment is identified quickly."

"PRECISION Panc aims to transform how we treat pancreatic cancer by matching the right treatment to the right patient."

Initiated by University of Glasgow professor Andrew Biankin, the programme focuses on expediting the recruitment and enrolment process during clinical trials.

The molecular profile of each individual cancer will be utilised by the researchers to provide patients and their doctor with a list of trials that could be beneficial.

The initial part of the research will aim to determine the best way to collect and profile patient tissue samples.

University researchers will analyse up to five samples extracted from a tumour of each patient during the diagnosis.

Image: New project for pancreatic cancer trials. Photo: courtesy of Cancer Research UK.